Cannabis use is associated with reduced prevalence of progressive stages of alcoholic liver disease

摘要

Abstract Background Abusive alcohol use has well‐established health risks including causing liver disease ( ALD ) characterized by alcoholic steatosis ( AS ), steatohepatitis ( AH ), fibrosis, cirrhosis ( AC ) and hepatocellular carcinoma ( HCC ). Strikingly, a significant number of individuals who abuse alcohol also use Cannabis, which has seen increased legalization globally. While cannabis has demonstrated anti‐inflammatory properties, its combined use with alcohol and the development of liver disease remain unclear. Aim The aim of this study was to determine the effects of cannabis use on the incidence of liver disease in individuals who abuse alcohol. Methods We analysed the 2014 Healthcare Cost and Utilization Project‐Nationwide Inpatient Sample ( NIS ) discharge records of patients 18?years and older, who had a past or current history of abusive alcohol use (n?=?319?514). Using the International Classification of Disease, Ninth Edition codes, we studied the four distinct phases of progressive ALD with respect to three cannabis exposure groups: non‐cannabis users (90.39%), non‐dependent cannabis users (8.26%) and dependent cannabis users (1.36%). We accounted for the complex survey sampling methodology and estimated the adjusted odds ratio ( AOR ) for developing AS , AH , AC and HCC with respect to cannabis use ( SAS 9.4). Results Our study revealed that among alcohol users, individuals who additionally use cannabis (dependent and non‐dependent cannabis use) showed significantly lower odds of developing AS , AH , AC and HCC ( AOR : 0.55 [0.48‐0.64], 0.57 [0.53‐0.61], 0.45 [0.43‐0.48] and 0.62 [0.51‐0.76]). Furthermore, dependent users had significantly lower odds than non‐dependent users for developing liver disease. Conclusions Our findings suggest that cannabis use is associated with a reduced incidence of liver disease in alcoholics.